Wang Li, Zhang Zhixin, Luo Gan, Wang Ying, Du Ke, Gao Xiaoyan
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Front Mol Biosci. 2023 Feb 20;10:1147910. doi: 10.3389/fmolb.2023.1147910. eCollection 2023.
Hyperlipidemia is a common metabolic disorder with presence of excess fat or lipids in the blood, may induce liver injury, oxidative stress and inflammatory. Xuezhiping capsule (XZP) is a famous Chinese patent medicine clinically used for anti-hyperlipidemia. However, the regulation mechanism of XZP on hyperlipidemia has not been elucidated so far. This study aimed to explore the effects of XZP on hypolipidemic, antioxidant and anti-inflammatory effects, and the potential mechanism by a combination of untargeted metabolomics and 16S rRNA sequencing. The results indicated that XZP reduced the level of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), increased the level of high density liptein cholesterol (HDL-C), alleviated excessive accumulation of lipid droplets in liver. Biochemical indexes of liver function including gamma glutamyl transferase (GGT) and glutamic oxaloacetic transaminase (GOT) in liver were remarkably decreased. Meanwhile, XZP increased the level of oxidative stress biochemical indexes including superoxide dismutase (SOD) and glutathione (GSH). In addition, XZP increased the level of peroxisome proliferators-activated receptors α (PPARα), acetyl CoA carboxylase 1 (ACOX1) and cholesterol 7-alpha hydroxylase (CYP7A1) in liver, and improved lipid metabolism in serum, liver and fecal lipid metabolism. XZP increased diversity index and the ratio of Firmicutes and Bacteroidetes, regulated seventeen genera, and illustrated strong correlations with liver lipid metabolism and phenotypic indicators. These findings suggest that XZP reduced blood lipid and liver lipid, protected liver function, anti inflammation and anti-oxidation, ameliorate lipid metabolic disorders by modulating alpha linolenic acid and linoleic acid metabolism, bile acid metabolism, arachidonic acid metabolism, and regulated gut microbiota composition of high-fat diet (HFD) hamsters.
高脂血症是一种常见的代谢紊乱疾病，血液中存在过量的脂肪或脂质，可能导致肝损伤、氧化应激和炎症。血脂平胶囊（XZP）是一种临床上用于抗高脂血症的著名中成药。然而，迄今为止，XZP对高脂血症的调节机制尚未阐明。本研究旨在通过非靶向代谢组学和16S rRNA测序相结合的方法，探讨XZP对降血脂、抗氧化和抗炎的作用及其潜在机制。结果表明，XZP降低了总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）水平，提高了高密度脂蛋白胆固醇（HDL-C）水平，减轻了肝脏中脂滴的过度积累。肝脏中包括γ-谷氨酰转移酶（GGT）和谷草转氨酶（GOT）在内的肝功能生化指标显著降低。同时，XZP提高了包括超氧化物歧化酶（SOD）和谷胱甘肽（GSH）在内的氧化应激生化指标水平。此外，XZP提高了肝脏中过氧化物酶体增殖物激活受体α（PPARα）、乙酰辅酶A羧化酶1（ACOX1）和胆固醇7-α羟化酶（CYP7A1）的水平，并改善了血清、肝脏和粪便脂质代谢中的脂质代谢。XZP增加了多样性指数以及厚壁菌门和拟杆菌门的比例，调节了17个属，并与肝脏脂质代谢和表型指标显示出强相关性。这些发现表明，XZP通过调节α-亚麻酸和亚油酸代谢、胆汁酸代谢、花生四烯酸代谢，降低高脂饮食（HFD）仓鼠的血脂和肝脂，保护肝功能，抗炎抗氧化，改善脂质代谢紊乱，并调节肠道微生物群组成。
